59
Views
48
CrossRef citations to date
0
Altmetric
Original Articles

Toxicity of abrin and ricin in mice and dogs

, , &
Pages 1073-1084 | Received 14 Jun 1979, Accepted 16 Jul 1979, Published online: 20 Oct 2009
 

Abstract

Mice and dogs were treated iv with the cytostatic proteins abrin and ricin and observed for clinical, biochemical, and morphological aberrations. In both mice and dogs death occurred within a narrow dose range. Dogs given toxic doses of ricin and abrin showed weakness, anorexia, apathy, and moderate fever. No signs attributable to the central nervous system were observed. Dogs dying from intoxication expired after 15–40 h. After nonlethal doses the animals recovered, apparently completely, in 1–3 wk. No delayed changes were observed in dogs after 4 mo.

Abrin and ricin, in contrast to most other cytostatic agents, did not inhibit myelopoiesis. However, after sublethal doses a rapid but transient decrease of peripheral thrombocytes was observed. No evidence for specific liver damage or impairment of kidney function was obtained. Few abnormalities were observed at autopsy or on microscopic and electron microscopic examination of the tissues, in contrast to the findings of some earlier investigators.

The results indicate that in mice and dogs given sublethal doses of highly purified toxins the symptoms are reversible. There was no finding militating against a phase I clinical trial.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.